20/20 Biolabs, Inc. Common Stock
AIDX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.12M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.12 Million |
|---|---|
| Enterprise Value | $-1,388,440.00 |
| Earnings per Share | $-0.6 |
| Beta | 1.54 |
| Outstanding Shares | 10,790,722 |
Return
| Return on Equity | -428.70% |
|---|---|
| Return on Assets | -113.47% |
| Return on Invested Capital | -132.61% |
Valuation & Multiples
| P/E Ratio | -0.28 |
|---|---|
| PEG | -0.23 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -0.39 |
| Enterprise Value to EBIT | 0.17 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -1.32 |
| Debt to Equity | 0.64 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 2, 2026
EPS Estimate
$-0.12
Consensus analyst estimateRevenue Estimate
$636,000
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 5.00% |
|---|---|
| Total Invested | $335▼ 99.89% |
| Investors Holding | 1▼ 14.00% |
About 20/20 Biolabs, Inc. Common Stock
13 employees
CEO: Jonathan Cohen
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offer...